Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
José Otto ReusingEmanoela B FeitosaFabiana AgenaLígia C PierrottiLuiz S F AzevedoCamille N KottonElias David-NetoPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2018)
These data indicate that antiviral prophylaxis adequately prevented CMV in seropositive recipients given ATG, but late disease still occurred. Low eGFR and low lymphocyte count at the end of prophylaxis may help identify patients at higher risk of CMV disease.